These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 28228261)

  • 1. Context-Dependent Effects of Amplified MAPK Signaling during Lung Adenocarcinoma Initiation and Progression.
    Cicchini M; Buza EL; Sagal KM; Gudiel AA; Durham AC; Feldser DM
    Cell Rep; 2017 Feb; 18(8):1958-1969. PubMed ID: 28228261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MEK1/2 inhibition elicits regression of autochthonous lung tumors induced by KRASG12D or BRAFV600E.
    Trejo CL; Juan J; Vicent S; Sweet-Cordero A; McMahon M
    Cancer Res; 2012 Jun; 72(12):3048-59. PubMed ID: 22511580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of tumorigenic cells in Kras(G12D)-induced lung adenocarcinoma.
    Cho HC; Lai CY; Shao LE; Yu J
    Cancer Res; 2011 Dec; 71(23):7250-8. PubMed ID: 22088965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutationally activated PIK3CA(H1047R) cooperates with BRAF(V600E) to promote lung cancer progression.
    Trejo CL; Green S; Marsh V; Collisson EA; Iezza G; Phillips WA; McMahon M
    Cancer Res; 2013 Nov; 73(21):6448-61. PubMed ID: 24019382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models.
    Ji H; Wang Z; Perera SA; Li D; Liang MC; Zaghlul S; McNamara K; Chen L; Albert M; Sun Y; Al-Hashem R; Chirieac LR; Padera R; Bronson RT; Thomas RK; Garraway LA; Jänne PA; Johnson BE; Chin L; Wong KK
    Cancer Res; 2007 May; 67(10):4933-9. PubMed ID: 17510423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Braf kinase-inactive mutant induces lung adenocarcinoma.
    Nieto P; Ambrogio C; Esteban-Burgos L; Gómez-López G; Blasco MT; Yao Z; Marais R; Rosen N; Chiarle R; Pisano DG; Barbacid M; Santamaría D
    Nature; 2017 Aug; 548(7666):239-243. PubMed ID: 28783725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening for tumor suppressors: Loss of ephrin receptor A2 cooperates with oncogenic KRas in promoting lung adenocarcinoma.
    Yeddula N; Xia Y; Ke E; Beumer J; Verma IM
    Proc Natl Acad Sci U S A; 2015 Nov; 112(47):E6476-85. PubMed ID: 26542681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD44 promotes Kras-dependent lung adenocarcinoma.
    Zhao P; Damerow MS; Stern P; Liu AH; Sweet-Cordero A; Siziopikou K; Neilson JR; Sharp PA; Cheng C
    Oncogene; 2013 Oct; 32(43):5186-90. PubMed ID: 23208496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The ERBB network facilitates KRAS-driven lung tumorigenesis.
    Kruspig B; Monteverde T; Neidler S; Hock A; Kerr E; Nixon C; Clark W; Hedley A; Laing S; Coffelt SB; Le Quesne J; Dick C; Vousden KH; Martins CP; Murphy DJ
    Sci Transl Med; 2018 Jun; 10(446):. PubMed ID: 29925636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nrf2 prevents initiation but accelerates progression through the Kras signaling pathway during lung carcinogenesis.
    Satoh H; Moriguchi T; Takai J; Ebina M; Yamamoto M
    Cancer Res; 2013 Jul; 73(13):4158-68. PubMed ID: 23610445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. C-Raf is required for the initiation of lung cancer by K-Ras(G12D).
    Karreth FA; Frese KK; DeNicola GM; Baccarini M; Tuveson DA
    Cancer Discov; 2011 Jul; 1(2):128-36. PubMed ID: 22043453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice.
    Hermann PC; Sancho P; Cañamero M; Martinelli P; Madriles F; Michl P; Gress T; de Pascual R; Gandia L; Guerra C; Barbacid M; Wagner M; Vieira CR; Aicher A; Real FX; Sainz B; Heeschen C
    Gastroenterology; 2014 Nov; 147(5):1119-33.e4. PubMed ID: 25127677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectors and potential targets selectively upregulated in human KRAS-mutant lung adenocarcinomas.
    Li J; Sordella R; Powers S
    Sci Rep; 2016 Jun; 6():27891. PubMed ID: 27301828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mouse tissues that undergo neoplastic progression after K-Ras activation are distinguished by nuclear translocation of phospho-Erk1/2 and robust tumor suppressor responses.
    Parikh N; Shuck RL; Nguyen TA; Herron A; Donehower LA
    Mol Cancer Res; 2012 Jun; 10(6):845-55. PubMed ID: 22532587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PIK3CA(H1047R) Accelerates and Enhances KRAS(G12D)-Driven Lung Tumorigenesis.
    Green S; Trejo CL; McMahon M
    Cancer Res; 2015 Dec; 75(24):5378-91. PubMed ID: 26567140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of Mutant
    Zhou X; Padanad MS; Evers BM; Smith B; Novaresi N; Suresh S; Richardson JA; Stein E; Zhu J; Hammer RE; O'Donnell KA
    Mol Cancer Res; 2019 Feb; 17(2):594-603. PubMed ID: 30409919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of MEK1/2-ERK1/2 signaling during NNK-induced lung carcinogenesis in female A/J mice.
    Yamakawa K; Yokohira M; Nakano Y; Kishi S; Kanie S; Imaida K
    Cancer Med; 2016 May; 5(5):903-13. PubMed ID: 26864819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thrombospondin-1 mediates oncogenic Ras-induced senescence in premalignant lung tumors.
    Baek KH; Bhang D; Zaslavsky A; Wang LC; Vachani A; Kim CF; Albelda SM; Evan GI; Ryeom S
    J Clin Invest; 2013 Oct; 123(10):4375-89. PubMed ID: 24018559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NOS2 enhances KRAS-induced lung carcinogenesis, inflammation and microRNA-21 expression.
    Okayama H; Saito M; Oue N; Weiss JM; Stauffer J; Takenoshita S; Wiltrout RH; Hussain SP; Harris CC
    Int J Cancer; 2013 Jan; 132(1):9-18. PubMed ID: 22618808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MAP4K4 is a novel MAPK/ERK pathway regulator required for lung adenocarcinoma maintenance.
    Gao X; Chen G; Gao C; Zhang DH; Kuan SF; Stabile LP; Liu G; Hu J
    Mol Oncol; 2017 Jun; 11(6):628-639. PubMed ID: 28306189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.